The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions.If you have any queries about the SPCs on our website then please e-mail

Cevac IBD 2512 L lyophilisate for oral suspension for chickens

Ceva Santé AnimaleVPA10815/020/001

Main Information

Trade NameCevac IBD 2512 L lyophilisate for oral suspension for chickens
Active SubstancesLive infectious bursal disease (ibd) virus strain, winterfield 2512, g-61
Dosage FormLyophilisate for oculonasal suspension/use in drinking water
Licence HolderCeva Santé Animale
Licence NumberVPA10815/020/001

Group Information

ATC CodeQI01AD09 avian infectious bursal disease virus (gumboro disease)
Therapeutic ClassImmunological - Live Vaccine


License statusAuthorised
Licence Issued14/12/2012
Legal StatusPOM: Prescription Only Medicine as defined in relevant national legislation


Summary of Product Characteristics *PDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
VariationsNo document available

* The PDF document, together with the national-specific product information on this page, constitute the authorised SPC
« Back